Loading…
Loading…
BFLY does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BFLY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BFLY and 80,000+ other tickers.
See exactly how BFLY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BFLY and 80,000+ other tickers.
Butterfly Network, Inc. functions as a digital health enterprise, specializing in the invention, production, and global commercialization of cutting-edge ultrasound imaging technologies for both domestic and international markets. The company's innovative product portfolio includes the portable Butterfly iQ, a versatile single-probe system capable of whole-body ultrasound imaging, and the Butterfly iQ+, a point-of-care ultrasound device engineered to connect effortlessly with smartphones, tablets, and existing hospital computer networks. Additionally, Butterfly Blueprint is offered as a…
NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound, cloud software and AI, today announced that it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 15, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman; John Doherty, EVP, Chief Financial Officer; and Megan Carlson, SVP, Accounting & Finance – Chief Accounting.
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound, programmable cloud software and AI, and Merge Labs today announced a multi-year licensing agreement through Butterfly Embedded™. The agreement gives Merge access to Butterfly's Poseidon Family of Ultrasound-on-Chip™ technology for the development of ultrasound-based brain-computer interfaces (BCI). Merge Labs was founded with the long-term mi.
Louise S. Phanstiel acquired ~115,000 shares at $8.68 per share, representing a total transaction value of $1.0 million. The purchase increased the director's total equity holdings by 20% and indirect holdings by 62%.
68,346 shares were sold for ~$684,143 on August 10, 2026. The transaction represents a 0.89% reduction in direct equity holdings.
Butterfly Network (BFLY) traces back to a not-so-modest aspiration of one co-founder, to change the world, and a fortunate introduction by his professor to a visionary tech entrepreneur. BFLY is doing that through its pioneering ultrasound on a chip. A scanner sends images to an iPhone or similar device. That makes ultrasound doable pretty much anywhere. That's a huge deal. Cumbersome logistics cause many to refrain from being scanned as regularly as they should, often to bad and sometimes tragic results.